Enanta Pharmaceuticals
ENTA
146 hedge funds and large institutions have $869M invested in Enanta Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 22 closing their positions.
5,897% more call options, than puts
Call options by funds: $10.6M | Put options by funds: $176K
16% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 49
2.64% less ownership
Funds ownership: 95.08% → 92.44% (-2.6%)
8% less funds holding
Funds holding: 159 → 146 (-13)
15% less capital invested
Capital invested by funds: $1.02B → $869M (-$153M)
55% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 22
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$12.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.14M |
| 3 |
BlackRock
New York
|
+$6.03M |
| 4 |
CC
Commodore Capital
New York
|
+$5.47M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$5.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$46.5M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$24.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$11.4M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$3.71M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.03M |
ENTA Hedge Fund Activity: Q4 2022 in Review
146 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2022, worth a combined $869M — down 15% from $1.02B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ENTA and 10 opened new positions — a net loss of 12 holders — while 49 trimmed existing stakes and 57 added.
The largest buyer was UBS AM, adding an estimated $12.2M. The largest seller was RA Capital Management, exiting entirely with an estimated $46.5M sold.
- 146 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2022, down from 159 in Q3 2022.
- Funds reported $869M of Enanta Pharmaceuticals stock for Q4 2022, down 15% quarter-over-quarter.
- 10 funds opened new Enanta Pharmaceuticals positions in Q4 2022 and 22 closed out, a net change of -12 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2022 was UBS AM, an estimated $12.2M added.
- The largest Enanta Pharmaceuticals seller in Q4 2022 was RA Capital Management, an estimated $46.5M sold.
Based on aggregated 13F filings for Q4 2022.